ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.
ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.
复制标题
DOI：
10.4155/tde.12.61
复制
发表时间：
2012-07
影响因子：
4.2
通讯作者：
Gandhi V
中科院分区：
文献类型：
--
作者：
Peng X;Gandhi V
靶向肿瘤细胞是提高肿瘤治疗选择性的重要策略。随着癌症生物学研究的深入，我们知道癌细胞通常处于增加的氧化应激状态。癌细胞中高水平的活性氧已被用于开发新的治疗策略，以优先杀死癌细胞。我们的团队，在其他团队中，已经使用硼酸/酯作为触发器来开发ros激活的抗癌前药，靶向癌细胞。选择性是通过硼酸盐与H2O2之间的特异性反应和通过硼酸盐有效掩盖药物前药毒性来实现的。通过二茂铁介导氧化激活的前药也被开发出来，以提高抗癌药物的选择性。我们描述了如何将ros激活策略用于进一步开发新的靶向ros的前药，最终导致新的方法和/或联合技术，以更有效和选择性地治疗癌症。
Targeting tumor cells is an important strategy to improve the selectivity of cancer therapies. With the advanced studies in cancer biology, we know that cancer cells are usually under increased oxidative stress. The high level of reactive oxygen species in cancer cells has been exploited for developing novel therapeutic strategies to preferentially kill cancer cells. Our group, amongst others, have used boronic acids/esters as triggers for developing ROS-activated anticancer prodrugs that target cancer cells. The selectivity was achieved by combining a specific reaction between boronates and H2O2 with the efficient masking of drug toxicity in the prodrug via boronates. Prodrugs activated via ferrocene-mediated oxidation have also been developed to improve the selectivity of anticancer drugs. We describe how the strategies of ROS-activation can be used for further development of new ROS-targeting prodrugs, eventually leading to novel approaches and/or combined technology for more efficient and selective treatment of cancers.